PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotech company focused on urothelial and specialty cancers, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for ZUSDURI, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI, utilizing UroGen's proprietary sustained release RTGel® technology, consists of mitomycin and sterile hydrogel designed for potent tumor ablation. This landmark approval is based on positive results from the Phase 3 ENVISION trial, which demonstrated a 78% complete response rate at 3 months, with 79% of those patients remaining event-free 12 months later. This approval marks a significant advancement in the treatment of bladder cancer, providing an FDA-approved option for the estimated 59,000 U.S. patients facing recurrent LG-IR-NMIBC each year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.